Announcements Trials

Browse Landscape

Phase

Phase 1/2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 36 Breast Neoplasms 29 Pancreatic Neoplasms 20 Rectal Neoplasms 17 Stomach Neoplasms 16 Neoplasm Metastasis 16 Neoplasms 12 Esophageal Neoplasms 8 Triple Negative Breast Neoplasms 7 Colonic Neoplasms 7 Colorectal Cancer Metastatic 6 Carcinoma, Non-Small-Cell Lung 5 Squamous Cell Carcinoma of Head and Neck 4 Brain Neoplasms 4 Adenocarcinoma 4 Head and Neck Neoplasms 3 Gastrointestinal Neoplasms 3 Biliary Tract Neoplasms 3 Bile Duct Neoplasms 3 Advanced Solid Tumors 3 Sarcoma 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Ovarian Neoplasms 2 Melanoma 2 Lymphoma, Non-Hodgkin 2 Liver Neoplasms 2 Diabetes Mellitus, Insulin-Dependent, 12 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Carcinoma, Hepatocellular 2

Interventions

pembrolizumab 1 liposomal doxorubicin 1 Everolimus 1 Capecitabine 1 AZD7648 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Advanced Malignancies × Capecitabine × Clear all

NCT01079702 2010-03-03

m-TOR

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 1/2 Unknown

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡